Hydroxyurea placebo
Phase 3
Merck & Co.Hydroxyurea placebo is one of 9 therapeutic programs targeting Essential Thrombocythemia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
8 competitors in Essential Thrombocythemia
#DrugCompanyPhaseTrials
1Droxia
TTheravia
Approved
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Trisenox
CCephalon
Approved
Vonjo
SSobi, Inc.
Phase 3
BESREMI
PPharmaEssentia
Phase 3
Bomedemstat
Merck & Co.Phase 3
Inrebic
Bristol-Myers SquibbPhase 3
Hydroxyurea placebo
Merck & Co.Phase 3
IMG-7289
TThe University of Texas Health Science Center at San Antonio
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Essential Thrombocythemia1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Hydroxyurea placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company